104,723 Abivax SA Sponsored ADR $ABVX Shares Bought by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. increased its holdings in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 280.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 142,083 shares of the company’s stock after acquiring an additional 104,723 shares during the period. Abivax comprises 1.3% of Nan Fung Trinity HK Ltd.’s investment portfolio, making the stock its 29th biggest holding. Nan Fung Trinity HK Ltd. owned 0.16% of Abivax worth $14,069,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in ABVX. Versant Capital Management Inc acquired a new position in Abivax during the 2nd quarter valued at about $30,000. Assetmark Inc. raised its stake in shares of Abivax by 41.5% in the first quarter. Assetmark Inc. now owns 886 shares of the company’s stock worth $99,000 after purchasing an additional 260 shares during the last quarter. Troluce Capital Advisors LLC purchased a new stake in shares of Abivax in the second quarter worth approximately $133,000. Engineers Gate Manager LP purchased a new stake in shares of Abivax in the second quarter worth approximately $284,000. Finally, Goldstein Advisors LLC lifted its holdings in shares of Abivax by 49.6% in the third quarter. Goldstein Advisors LLC now owns 2,390 shares of the company’s stock valued at $237,000 after purchasing an additional 792 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

Analysts Set New Price Targets

ABVX has been the topic of several analyst reports. Guggenheim reaffirmed a “buy” rating and set a $175.00 target price on shares of Abivax in a research report on Tuesday, October 20th. Barclays reissued an “overweight” rating and issued a $148.00 price target on shares of Abivax in a research report on Tuesday, September 22nd. The Goldman Sachs Group assumed coverage on Abivax in a research note on Wednesday, September 9th. They set a “buy” rating and a $155.00 price objective on the stock. Piper Sandler restated an “overweight” rating on shares of Abivax in a research note on Wednesday, October 21st. Finally, Wedbush cut their price objective on shares of Abivax from $118.00 to $96.00 and set a “neutral” rating on the stock in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $155.00.

Abivax Stock Performance

NASDAQ:ABVX opened at $90.20 on Friday. Abivax SA Sponsored ADR has a 52 week low of $69.81 and a 52 week high of $148.83. The firm has a 50-day moving average price of $95.37 and a two-hundred day moving average price of $112.69. The firm has a market cap of $7.90 billion, a price-to-earnings ratio of -14.88 and a beta of 1.36.

Abivax (NASDAQ:ABVX) last announced its earnings results on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79). The firm had revenue of $1.37 million during the quarter, compared to analysts’ expectations of $0.80 million. As a group, sell-side analysts forecast that Abivax SA Sponsored ADR will post -4.14 earnings per share for the current year.

Abivax Company Profile

Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.